Novo Nordisk Stock Options
| NVO Stock | USD 108.67 1.87 1.75% |
Novo Nordisk's latest option contracts expiring on 2024-12-06 are carrying combined implied volatility of 0.14 with a put-to-call open interest ratio of 0.58 over 75 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on 2024-12-06. The total put volume is at 829, with calls trading at the volume of 829. This yields a 0.55 put-to-call volume ratio.
Open Interest Against 2024-12-06 Option Contracts
2024-12-06
The chart above shows Novo Nordisk's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Novo Nordisk's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Novo Nordisk's option, there is no secondary market available for investors to trade.
Novo Nordisk's option chain provides insight into all available option contracts written on Novo Nordisk's stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Novo Nordisk's stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Novo option contract.
In The Money vs. Out of Money Option Contracts on Novo Nordisk
Analyzing Novo Nordisk's in-the-money options over time can help investors to take a profitable long position in Novo Nordisk regardless of its overall volatility. This is especially true when Novo Nordisk's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Novo Nordisk's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Novo Nordisk's stock while costing only a fraction of its price.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Please note that buying 'in-the-money' options on Novo Nordisk lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Novo Nordisk's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Novo Nordisk contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Novo Stock moves the wrong way.
Novo Nordisk AS In The Money Call Balance
When Novo Nordisk's strike price is surpassing the current stock price, the option contract against Novo Nordisk AS stock is said to be in the money. When it comes to buying Novo Nordisk's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Novo Nordisk AS are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Novo Current Options Market Mood
Novo Nordisk's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Novo Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Novo Nordisk's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Novo Nordisk's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Novo contract
Base on the Rule 16, the options market is currently suggesting that Novo Nordisk AS will have an average daily up or down price movement of about 0.00875% per day over the life of the 2024-12-06 option contract. With Novo Nordisk trading at USD 108.67, that is roughly USD 0.009509. If you think that the market is fully incorporating Novo Nordisk's daily price movement you should consider buying Novo Nordisk AS options at the current volatility level of 0.14%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Novo |
Purchasing Novo Nordisk options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Novo calls. Remember, the seller must deliver Novo Nordisk AS stock to the call owner when a call is exercised.
Novo Nordisk Option Chain
When Novo Nordisk's strike price is surpassing the current stock price, the option contract against Novo Nordisk AS stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
2024-12-062024-12-132024-12-202024-12-272025-01-032025-01-102025-01-172025-02-212025-03-212025-04-172025-06-202025-09-192026-01-162027-01-15
Novo Nordisk's option chain is a display of a range of information that helps investors for ways to trade options on Novo. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Novo. It also shows strike prices and maturity days for a Novo Nordisk against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. Novo Nordisk Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Novo Nordisk Market Cap Over Time
Market Cap |
| Timeline |
Novo Total Stockholder Equity
Total Stockholder Equity |
|
Novo Nordisk Corporate Directors
| Kasim Kutay | Director | Profile | |
| Sylvie Gregoire | Independent Director | Profile | |
| Mette Jensen | Director, Employee Representative | Profile | |
| Thomas Rantzau | Director, Employee Representative | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.